MINARIS
LIVE

Serial Number

90057531

Owner

HITACHI CHEMICAL COMPANY, LTD.

Attorney

Kate Sherlock

Filing Date

Jul 16, 2020

Add to watchlist:

No watchlists yet
View on USPTO

MINARIS Trademark

Serial Number: 90057531 • Registration: 6823488

MINARIS is a trademark filed by HITACHI CHEMICAL COMPANY, LTD. on July 16, 2020. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

HITACHI CHEMICAL COMPANY, LTD. (37 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

RESONAC CORPORATION (38 trademarks)

13-9, SHIBA DAIMON 1-CHOME
TOKYO 105-8518 , JP

Entity Type: 29

SHOWA DENKO MATERIALS CO., LTD. (12 trademarks)

9-2, MARUNOUCHI 1-CHOME
TOKYO 100-6606 , JP

Entity Type: 29

MINARIS REGENERATIVE MEDICINE CO., LTD. (4 trademarks)

1, EBISU-CHO, KANAGAWA-KU
KANAGAWA 221-0024 , JP

Entity Type: 29

Trademark Details

Filing Date

July 16, 2020

Registration Date

August 23, 2022

Published for Opposition

June 7, 2022

Goods & Services

Medical services, namely, contracted cell culturing and tissue culturing for medical purposes; medical advisory services, namely, advisory services in the field of contracted cell culturing and tissue culturing for medical purposes; medical services, namely, separation and cultivation of body tissues and cells for medical purposes; information, advice and consultancy services relating to medical services and regenerative medicine; human tissue bank services; providing medical information; medical, medicinal and pharmaceutical consultancy; isolation, collection and preservation of blood components including cells or stem cells obtained from umbilical cord blood, bone marrow, placenta and other parts of the human body, hematopoietic and immune system cells, genetically or otherwise modified cells, cells which are propagated, cultivated and expanded in bioreactors, cells for the purpose of tissue regeneration, and cells of human or animal origin

Pharmaceutical research and development services, namely, contracted cell culturing and tissue culturing for scientific purposes; scientific and technological services, namely, testing, inspection for quality control purposes, and research in the field of cell culture and tissue culture, and consultancy and information services relating thereto; pharmaceutical research and development advisory services, namely, advisory services in the field of cell culturing for scientific purposes; research and product development services in the field of cell culture and tissue culture, and consultancy relating thereto; scientific consulting and research services relating to the isolation and cultivation of body tissues and cells; advisory services for pharmaceutical drug development; scientific testing and research services in the field of pharmaceuticals and biotechnology, and advisory services relating thereto; contracted development of biological cell manufacturing process; scientific laboratory services, namely, the cultivation or modification of hematopoietic and immune system cells, genetically or otherwise modified cells, cells which are propagated, cultivated and expanded in bioreactors, cells for the purpose of tissue regeneration into living drugs.; quality control services in the field of cell culture and tissue culture, and consultancy relating thereto; quality control of cell and living tissue for others

Contract manufacturing in the field of biological cells; contract manufacturing of cell tissue; contracted biological cell processing; information, advice and consultancy services relating to biological cell manufacturing; contract manufacturing in the field of biologics and pharmaceuticals; contracted cell culturing and tissue culturing in the nature of custom processing and manufacturing in the field of biological cells and tissues; advisory services in the field of cell culturing in the nature of advisory services in the field of custom processing and manufacturing in the field of biological cells; contract manufacturing of cell therapies, hematopoietic and immune system cells, genetically or otherwise modified cells, cells which are propagated, cultivated and expanded in bioreactors, cells for the purpose of tissue regeneration

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 6, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 6, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 6, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 6, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 6, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 6, 2026 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 5, 2025 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 19, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 19, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 19, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 19, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 19, 2025 COAR
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 11, 2024 ASCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 3, 2023 ASGN
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 23, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 23, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 7, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 7, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 18, 2022 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Apr 29, 2022 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 1, 2022 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 31, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 3, 2022 CRFA
ASSIGNED TO LIE
Mar 2, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 28, 2022 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 14, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 14, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 14, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 17, 2021 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 18, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 18, 2021 GNSL
SUSPENSION LETTER WRITTEN
Feb 18, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 26, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 25, 2021 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 6, 2021 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 6, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 6, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 6, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 6, 2020 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 14, 2020 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 13, 2020 NWOS
NEW APPLICATION ENTERED
Jul 20, 2020 NWAP